Competitive RisksLIVN's OSPREY study included patients with complete concentric collapse, whereas INSP's pivotal studies excluded these patients, potentially giving LIVN a competitive advantage.
Guidance ConcernsThe company's lower-than-expected 2Q guidance may worry some investors.
Sales ForecastQ2 sales are expected to be below prior expectations, with management forecasting growth lower than consensus.